British National Formulary 68

 Description

This Medical Association and Royal Pharmaceutical Society of Great Britain source of information, British National Formulary 68 (September 2014), is developed by MedHand Mobile Libraries. Improve your performance with relevant, valid material which is accessed quickly and with minimal effort in the palm of your hand using MedHand’s patented technology.

Important: This application is downloaded on your device and it securely enables instant and uninterrupted access wherever you are as it does not rely on a network connection while in use. The application is a single edition only; to stay updated it is recommended to purchase the forthcoming editions as they are revised twice yearly.

The British National Formulary (BNF) provides up-to-date, practical guidance on prescribing, dispensing, and administering medicines. This essential reference reflects current best practice as well as legal and professional guidelines relating to the uses of medicines.
Content of the BNF reflects current best practice as well as legal and professional guidelines relating to the uses of medicines. The resource includes:
• Guidance on the drug management of common conditions
• Details of medicines prescribed within the UK with special reference to their uses, cautions, contra-indications, side-effects, doses and relative costs. This allows treatment to be tailored to the individual needs of each patient.
• Guidance on prescribing, monitoring, dispensing and adminstering medicines.
The content is updated every 6 months, making it an up-to-date source of prescribing advice for informed decision-making.
BNF 68 (September 2014) has been revised and revalidated to reflect changes in product availability, emerging safety concerns and shifts in clinical practice. Access to the latest edition of the BNF is vital for healthcare professionals, as there are a large number of updates from one edition to the next.
Some of the significant changes in this edition include:
• Updated guidance on the incidence of venous thromboembolism associated with combined hormonal contraceptives
• Updated oral doses of amoxicillin and ampicillin for children
• New MHRA restrictions on the use of domperidone following a review of the risks and benefits of its use
• Changes made to the recommendations on interchangeability of oral mesalazine preparations
• New MHRA advice on self-administration of adrenaline for anaphylaxis
• The dose of naloxone for acute opioid overdosage in adults and children has been revised
• Updates to recommendations on doses and indications of paracetamol in children
• Updates to guidance on the treatment of epilepsy

The BNF evaluates clinical evidence from diverse sources with information validated by a network of clinical experts and published under the authority of a Joint Formulary Committee

Authors: British Medical Association and Royal Pharmaceutical Society of Great Britain


downlaod link
mediafire